BFRG Bullfrog AI Holdings Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 17, 2024

 

BULLFROG AI HOLDINGS, INC.

(Exact name of registrant as specified in charter)

 

Nevada		001-41600		84-4786155
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

 

325 Ellington Blvd, Unit 317

Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

 

(240) 658-6710

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $ 0.00001 per share		BFRG		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
Tradeable Warrants		BFRGW		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure

 

On January 17, 2024, Bullfrog AI Holdings, Inc. issued a press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number		Description
Exhibit 99.1		Press Release dated January 17, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 17, 2024

 

BULLFROG AI HOLDINGS, INC.
By:	/s/ Vininder Singh
	Vininder Singh
	Chief Executive Officer

 

 

Exhibit 99.1

 

 

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

 

Gaithersburg, MD – January 17, 2024 – BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

 

“This collaboration marks a pivotal moment in psychiatric research,” said Vin Singh, CEO of BullFrog AI. “By employing our bfLEAP™ platform on LIBD’s unrivaled brain data, we’ve gained invaluable ground into unraveling the biological underpinnings of psychiatric disorders. These preliminary findings have the potential to not only deepen our understanding but also pave the way for developing more targeted and effective treatments that set the stage for us to seek out revenue-generating strategic partnerships with pharmaceutical companies.”

 

The proprietary data from LIBD included gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. Utilizing graph analytics, BullFrog AI and LIBD have, for the first time, clustered subjects based solely on their biological data, independent of their behavioral diagnoses. This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders. Moreover, it has revealed biological subtypes within individual disorders, offering a nuanced understanding that could lead to personalized treatment strategies.

 

Daniel R. Weinberger, M.D., Director and CEO of LIBD, added, “Our collaboration with BullFrog AI has enabled us to apply cutting-edge AI technologies to our extensive brain data. The preliminary results are provocative and offer novel insights at the gene level that may only be discoverable using these novel AI technologies, offering a new lens through which we can view and potentially treat brain disorders. This is an important first step towards personalized medicine in psychiatry.”

 

The market opportunity for new treatments in psychiatric disorders is vast and underserved. With increasing global awareness and demand for mental health solutions, this breakthrough presents a potential paradigm shift in treatment approaches. By identifying possible biological subtypes within disorders, BullFrog AI and LIBD are not only advancing scientific understanding but also opening doors to novel therapeutic pathways and personalized treatment strategies.

 

The agreement between the organizations, announced in September 2023, granted BullFrog AI exclusive access to LIBD’s brain data, with the potential to commercialize products or services derived from the collaboration. The partnership represents a unique synergy between AI-driven analysis and world-class neuropsychiatric research, setting a new standard in the pursuit of effective treatments for brain disorders.

 

 

 

About the Lieber Institute for Brain Development (LIBD)

 

The mission of the Lieber Institute for Brain Development and the Maltz Research Laboratories is to translate the understanding of basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research institute. The Lieber Institute’s brain repository of more than 4,000 human brains is the largest collection of postmortem brains for the study of neuropsychiatric disorders in the world.

 

About BullFrog AI

 

BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

 

For more information visit BullFrog AI at:

 

Website: https://bullfrogai.com

 

LinkedIn: https://www.linkedin.com/company/bullfrogai/

 

Safe Harbor Statement

 

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

 

Contact:

 

Investors

Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447

 

SOURCE: BullFrog AI Holdings, Inc.

 

v3.23.4

Cover	Jan. 17, 2024
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 17, 2024
Entity File Number	001-41600
Entity Registrant Name	BULLFROG AI HOLDINGS, INC.
Entity Central Index Key	0001829247
Entity Tax Identification Number	84-4786155
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	325 Ellington Blvd
Entity Address, Address Line Two	Unit 317
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	(240)
Local Phone Number	658-6710
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Common Stock, par value $ 0.00001 per share
Title of 12(b) Security	Common Stock, par value $ 0.00001 per share
Trading Symbol	BFRG
Security Exchange Name	NASDAQ
Tradeable Warrants
Title of 12(b) Security	Tradeable Warrants
Trading Symbol	BFRGW
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

---